Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Graft Polymer (UK) PLC ( (GB:GPL) ) is now available.
Graft Polymer (UK) Plc has announced its intent to acquire Awakn Life Sciences Corp., a clinical-stage biotechnology company specializing in therapeutics for substance use and mental health disorders, for approximately £4.98 million. This acquisition, subject to several regulatory and shareholder approvals, aims to enhance Graft Polymer’s position in the UK biotechnology market by leveraging Awakn’s advanced clinical pipeline and complementary expertise in addiction and mental health therapeutics.
More about Graft Polymer (UK) PLC
Graft Polymer (UK) Plc is an innovative biotechnology company focused on co-developing therapeutics for mental health disorders. Its market focus is aligned with developing advanced clinical solutions targeting substance use and mental health issues, aiming for a significant impact within the UK biotechnology ecosystem.
YTD Price Performance: -58.62%
Average Trading Volume: 35,464,152
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £5.51M
See more insights into GPL stock on TipRanks’ Stock Analysis page.